Patents by Inventor Edward E. Baetge

Edward E. Baetge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6451601
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: September 17, 2002
    Assignee: Modex Therapeutiques, S.A.
    Inventors: Edward E. Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens
  • Publication number: 20020076787
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Application
    Filed: March 29, 2001
    Publication date: June 20, 2002
    Inventors: Edward E. Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens
  • Patent number: 6358739
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Modex Therapeutiques, S.A.
    Inventors: Edward E. Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens
  • Publication number: 20020025306
    Abstract: The instant invention involves methods of increasing the glucose responsiveness of pancreatic &bgr;-cells by providing a source of a glucoincretin. Also provided are methods of treating a disorder characterized by impaired &bgr;-cell function by providing a population of &bgr;-cells and a source of a glucoincretin. Additionally, the invention pertains to a population of purified &bgr;-cells and a kit for use in the treatment of a disorder characterized by impaired function.
    Type: Application
    Filed: January 5, 2001
    Publication date: February 28, 2002
    Inventors: Edward E. Baetge, William Pralong, Hamid Hussain Khan
  • Patent number: 6264941
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: July 24, 2001
    Assignee: Neurotech S.A.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Patent number: 5908623
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 1, 1999
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Patent number: 5676943
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: October 14, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Patent number: 5656481
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 12, 1997
    Assignee: Cyto Therapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Patent number: 5653975
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 5, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
  • Patent number: 5639275
    Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 17, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich